ondensed Consolidated Statement of Cash Flows – Unaudited or the six months ended 30 June	2023	2022
	US\$m	US\$m
it before taxation	1087.0	761.6
istments for:		
inance costs	281.7	229.2
Depreciation	169.2	164.5
Amortization of other intangible assets	67.1	71.2
Vrite-down of inventories to net realizable value oss on changes in fair value of biological assets	11.4 3.0	28.4 7.4
rovision for impairment losses	2.0	16.1
Employee share-based compensation benefit expenses	1.0	0.9
hare of profits less losses of associated companies and joint ventures	(230.4)	(164.9)
nterest income	(50.4)	(25.1)
ain on disposal of an associated company	(4.1)	(2.5)
ain on disposal of property, plant and equipment, net	(0.4)	-
ains on step acquisition of a joint venture	-	(65.7)
Others (including unrealized foreign exchange difference)	(143.1)	(2.3)
	1194.0	1018.8
ease in working capital	(231.0)	(154.7)
cash generated from operations rest received	963.0 47.7	864.1 22.2
rest paid	(262.4)	(213.4)
es paid	(219.7)	(213.4)
cash flows from operating activities	528.6	442.3
dends received from associated companies	168.7	149.3
ease in short-term deposits with original maturity of more than three months	60.3	19.1
osal of assets classified as held for sale	16.2	-
ease/(increase) in restricted cash	15.7	(50.8)
lends received from financial assets at fair value through		
er comprehensive income	14.8	14.1
osal of an associated company	5.6	2.5
lend received from a joint venture osal of a subsidiary company	4.3 3.3	8.8
osal of property, plant and equipment	2.8	2.1
osal of financial assets at fair value through other comprehensive income	1.9	30.1
stments in other intangible assets	(390.2)	(380.9)
stments in financial assets at fair value through other comprehensive income	(176.3)	-
nents for purchases of property, plant and equipment	(123.4)	(88.1)
tments in biological assets	(9.2)	(8.6)
-		(8.0)
isition of a subsidiary company	(1.3)	-
ents for purchases of investment properties	(0.5)	(1.0)
acquired from step acquisition of a joint venture	-	9.0
nent for retention amount payable	-	(650.0)
stment in financial assets at fair value through profit or loss	-	(20.0)
ased investments in joint ventures nces to joint ventures	-	(6.6) (5.2)
ased investments in associated companies	-	(5.2)
stment in an associated company	-	(4.0)
inces to an associated company	-	(0.6)
ash flows used in investing activities	(407.3)	(981.8)
eds from new bank borrowings and other loans	2415.9	2325.8
al contributions from non-controlling shareholders	13.8	10.1
ment of bank borrowings and other loans	(2166.5)	(2026.8)
ends paid to non-controlling shareholders by subsidiary companies	(160.8)	(93.9)
ipal portion of lease payments	(13.9)	(14.9)
ients for concession fees payable	(12.8)	(11.8)
ased investments in subsidiary companies	(1.3)	(0.3)
rchase of a subsidiary company's shares	-	(51.8)
rchase of shares	-	(5.6)
ents for purchase of shares under a long-term incentive plan	-	(1.0)
ash flows from financing activities	74.4	129.8
ncrease/(decrease) in cash and cash equivalents	195.7	(409.7)
and cash equivalents at 1 January ange translation	2457.8 46.5	3116.9 (133.2)
and cash equivalents at 30 June		
and cash equivalents at 30 June esenting	2700.0	2574.0
-		
and cash equivalents and short-term deposits as stated in		
and cash equivalents and short-term deposits as stated in condensed consolidated statement of financial position	2799.6	2641.6
and cash equivalents and short-term deposits as stated in condensed consolidated statement of financial position short-term deposits with original maturity of more than three months	2799.6 (99.6)	2641.6 (67.6)